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Background and PurposezzSeveral circulating biomarkers have been implicated in carotid 
atherosclerotic plaque rupture and thrombosis; however, their clinical utility remains unknown. 
The aim of this study was to determine the role of a large biomarker panel in the discrimination 
of symptomatic (S) vs. asymptomatic (A/S) subjects in a contemporary population with carotid 
artery stenosis (CS).
MethodszzProspective sampling of circulating cytokines and blood lipids was performed in 
300 unselected, consecutive patients with ≥50% CS, as assessed by duplex ultrasound (age 47-
83 years; 110 with A/S and 190 with S) who were referred for potential CS revascularization.
ResultszzCS severity and pharmacotherapy did not differ between the A/S and S patients. The 
median values of total cholesterol, low-density lipoprotein cholesterol, and lipoprotein(a) did not 
differ, but high-density lipoprotein (HDL) cholesterol was significantly higher (p<0.001) and 
triglycerides were lower (p=0.03) in the A/S-CS group than in the S-CS group. Interleukin-6 
(IL-6) and high-sensitivity C-reactive protein were higher (p=0.04 and p=0.07, respectively) in 
the S-CS group. Circulating visfatin, soluble CD 40 receptor ligand, soluble vascular cell adhe-
sion molecule, leptin, adiponectin, IL-1β, IL-8, IL-18, monocyte chemoattractant protein-1, my-
eloperoxidase, matrix metalloproteinases-8, -9, and -10, and fibrinogen were similar, but tissue 
inhibitor of matrix metalloproteinases-1 (TIMP) was reduced in S-CS compared to A/S-CS 
(p=0.02). Nevertheless, incorporation of TIMP and IL-6 did not improve the HDL-cholesterol 
receiver operating characteristics for S-CS status prediction. S-CS status was unrelated to angio-
graphic stenosis severity or plaque burden, as assessed by intravascular ultrasound (p=0.16 and 
p=0.67, respectively). Multivariate logistic regression analysis revealed low HDL-cholesterol to 
be the only independent predictor of CS symptoms, with an odds ratio of 1.81 (95% confidence 
interval=1.15-2.84, p=0.01) for HDL <1.00 mmol/L (first quartile) vs. >1.37 (third quartile). In 
S-CS, osteoprotegerin and lipoprotein-associated phospholipase A2 (Lp-PLA2) were elevated in 
those with recent vs. remote symptoms (p=0.01 and p=0.02, respectively).
ConclusionszzIn an all-comer CS population on contemporary pharmacotherapy, low HDL-
cholesterol (but not other previously implicated or several novel circulating biomarkers) is an 
independent predictor of S-CS status. In addition, an increase in circulating osteoprotegerin and 
Lp-PLA2 may transiently indicate S transformation of the carotid atherosclerotic plaque.
 J Clin Neurol 2013;9:165-175
Key Wordszz carotid artery stenosis, biomarkers, circulating cytokines, risk factors, stroke risk, 
HDL-cholesterol.
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Introduction
Risk stratification in asymptomatic subjects with atheroscle-
rotic extracranial internal carotid artery (ICA) stenosis (CS) 
is a major challenge in contemporary neurology and vascular 
medicine. In the general population, as many as 10-15% in-
dividuals aged over 55-60 years have significant (≥50%) CS.1 
Carotid plaque destabilization and rupture with thrombus 
formation is associated with 20-25% of ischemic strokes th-
rough embolization to the ipsilateral intracranial arteries and/
or an increase in stenosis severity resulting in hemodynamic 
compromise.1,2 Although CS is a well-documented and mod-
ifiable risk factor for ischemic stroke,1 population screening 
for CS is not recommended1 because of the difficulty identi-
fying those asymptomatic individuals who would benefit from 
carotid plaque removal (endarterectomy) or plaque sealing 
(stent) to reduce the stroke risk.1 For lesions with stenosis of 
≥50%, two large randomized trials (Asymptomatic Carotid 
Atherosclerosis Study, and Asymptomatic Carotid Surgery 
Trial) found no relationship between the stenosis severity and 
the risk of CS-associated stroke.1,3 Although the conversion of 
asymptomatic CS to symptomatic CS occurs relatively infre-
quently (≈0.3-2.0% per year),1,3 ≈80% of disabling strokes 
occur without any warning sign,1 indicating that for stroke-
affected patients with CS, any mechanical revascularization 
of CS (if offered) is already “too late”. Finally, routine diag-
nostic tools (such as duplex ultrasound, magnetic resonance 
angiography, or computed tomography angiography) remain 
largely ineffective for stratifying asymptomatic CS subjects 
according to stroke risk.1 Therefore, at present, interventional 
treatment of asymptomatic CS remains a statistical risk (with 
the number-needed-to-treat to prevent one stroke over 10 
years being as high as 20-100)1,3 rather than a risk-assessment-
based treatment of those who are likely to have a stroke de-
spite currently optimal medical management.
Several circulating biomarkers have been implicated in 
symptomatic transformation of the atherosclerotic carotid 
plaque through their association with plaque erosion, rupture, 
and thrombosis,4-10 and it has been proposed that such bio-
markers could play an important part in identifying those as-
ymptomatic subjects with CS who would benefit from carotid 
plaque removal or sealing.11,12 Since individual biomarkers 
may lack a sufficient discriminating power to impact clinical 
decision-making, it has been suggested that a “multimarker 
approach” will provide more powerful and clinically useful 
information.12,13 The value of multimarker analysis involving 
blood lipids and a large panel of circulating cytokines in pa-
tient discrimination according to CS-symptomatic status was 




This study involved an all-comer population of 300 consecu-
tive subjects with CS referred to a tertiary referral center14 for 
carotid artery revascularization decision-making during 2008-
2011. CS was at least 50%, as assessed by duplex ultrasound 
velocity; this was further confirmed by conventional angiog-
raphy. The patients consulted by an independent neurologist 
were classified either as “symptomatic” if they had a history 
of symptoms attributable to atherosclerotic CS, or “asympto-
matic” in the absence of such neurological symptoms. Based 
on the last occurrence of neurological symptoms, the symp-
tomatic subjects were further classified as those with last-
symptom occurrence during the preceding 6 months (labeled 
“recently” symptomatic) or those with a last-symptom episode 
more than 6 months prior (labeled “remotely” symptomatic).
Patients with restenotic or nonatherosclerotic carotid dis-
ease (e.g., Takayasu arteritis), known or suspected infection, 
chronic inflammatory disease, congestive heart failure (New 
York Heart Association class III/IV), or on renal replacement 
therapy were excluded. The following additional exclusion 
criteria were also applied: stroke or acute coronary syndrome 
during the preceding 2 weeks (to minimize the confounding 
effect of a temporary biomarker elevation as a result of the 
ischemic event), critical limb ischemia, inability to evaluate 
CS plaque burden with intravascular ultrasound (e.g., string-
sign ICA stenosis on noninvasive imaging), and a potential 
cause for past or future neurological symptoms other than ath-
erosclerotic carotid disease2 (e.g., atrial fibrillation, thrombo-
philia, or documented intracranial atherosclerosis). The dis-
tributions of classic risk factors (diabetes, hyperlipidemia, ar-
terial hypertension, and smoking) were evaluated, and detailed 
medical treatment was recorded on admission.
The study protocol was approved by the institutional Ethi-
cal Committee, and the patients gave informed written con-
sent to participate.
Laboratory data
Fasting venous blood was drawn between 7 and 9 a.m. from 
the antecubital vein with minimal stasis. Ethylenediaminetet-
raacetic acid-anticoagulated plasma and serum samples were 
centrifuged at 1600×g (at 4°C for 20 minutes for plasma and 
at 20°C for 10 minutes for serum), and the obtained aliquots 
were stored at -80°C before being analyzed. Lipid profile and 
creatinine were assayed by routine laboratory techniques. 
High-sensitivity C-reactive protein (hsCRP) was determined 
by an immunoturbidimetric assay (Roche). Fibrinogen was 
measured according to the Clauss method (Instrumentation 
Laboratory). Biomarkers were evaluated according to manu-
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facturer’s reagents and standards by using commercially av-
ailable high-sensitivity ELISA kits from the following manu-
facturers: total adiponectin and total leptin-ALPCO Diagno-
stics; soluble CD 40 receptor ligand (CD 40L), interleukin (IL)-
1β, IL-6, IL-8, and IL-18, matrix metalloproteinase (MMP)-
8, MMP-9, and MMP-10-R&D Systems; lipoprotein-associat-
ed phospholipase A2 (Lp-PLA2)-diaDexus; monocyte chemo-
attractant protein (MCP), myeloperoxidase (MPO), tissue in-
hibitor of matrix metalloproteinases-1 (TIMP), and soluble 
vascular cell adhesion molecule (sVCAM)-Bender MedSys-
tems; and total human lipoprotein a [Lp(a)]-BIOTEK; osteo-
protegerin (OPG) and visfatin-MBL International. All mea-
surements were performed in duplicate by technicians blind-
ed to the sample status, and the average value was used for an-
alysis. The intra- and interassay coefficients of variation were 
≤6.4% and ≤8.1%, respectively.
Imaging
A CS severity of ≥50% was determined by duplex sonogram 
(Toshiba Aplio PowerVision ultrasound machine equipped 
with a 4- to 11-MHz linear-array transducer) using the classic 
velocity criteria of peak-systolic velocity ≥125 cm/s, end-di-
astolic velocity ≥40 cm/s, and a visible plaque,1,14-16 and was 
further confirmed by catheter angiography.14 Of the initial 303 
screened patients, 3 were excluded because the catheter angio-
gram did not confirm a carotid lesion severity with a diameter 
stenosis of at least 50%. The presence of symptomatic periph-
eral arterial occlusive disease (PAD) was verified by noninva-
sive imaging (duplex ultrasound or computed tomography an-
giography) or a history of surgical or endovascular PAD in-
terventions. Consistent with our previously reported proto-
col,14 coronary angiography was performed routinely, and 
coronary artery disease was diagnosed from a history of cor-
onary revascularization or the presence of at least one signifi-
cant stenosis in a major branch on a coronary angiogram. To 
evaluate the burden of CS atheroma, intravascular ultrasound 
(IVUS) images were acquired with a commercially available 
rapid-exchange phased-array scanner (Eagle Eye, ChromaFlo 
application from Volcano Corp for improved vessel lumen/
plaque interface determination)17 in 293 subjects (97.7%). In 
seven patients (2.3%) the angiographically detected stenosis 
was considered too severe to attempt lesion crossing with an 
IVUS probe without predilatating the lesion.
Statistical analysis
Data were evaluated with Statistica 10.0. The distributions of 
all continuous variables were assessed using the Shapiro-Wilk 
test. Continuous data are expressed as median (first quartile-
third quartile) values and differences between groups were 
analyzed using a parametric t-test or Mann-Whitney test, as 
applicable. The categorical data are presented as the percent-
age and number of patients in the groups, and were compared 
using the χ2 test or the Fisher exact test. Biomarkers that were 
not interrelated were entered into receiver operating charac-
teristics (ROC) analysis for CS-symptomatic status predic-
tion. The biomarker cutoff values were calculated by using 
the Youden index. In addition, univariate and multivariate lo-
gistic regression analyses (including data log-transformation 
as necessary) were performed to identify the independent 
biomarkers with a discriminating power. All tests were two-
tailed, and the significance level was defined as p<0.05.
Results
Clinical presentation, carotid stenosis severity, 
and medical treatment
Patients with symptomatic ICA stenosis (n=190, 63.3%) had 
a history of cerebral stroke (n=127), retinal embolization (n= 
5), cerebral transient ischemic attack (TIA, n=79), or transient 
ocular blindness (n=23). The asymptomatic and symptomatic 
patient groups did not differ with respect to clinical character-
istics and carotid stenosis severity, as assessed by duplex so-
nogram (Table 1). Medical treatment on index hospital admis-
sion included the use of angiotensin-converting enzyme in-
hibitors or angiotensin receptor inhibitors (89.1% vs. 90.5% 
in asymptomatic vs. symptomatic patients, respectively), β-bl-
ockers (70.1% vs. 67.8%), calcium-channel blockers (35.5% 
vs. 32.1%), and diuretics (38.1% vs. 35.7%; p>0.1 for all). Ne-
arly all patients were on a statin (asymptomatic, 99.1%; symp-
tomatic, 100%). The groups were similar with respect to ator-
vastatin/simvastatin use (65.5%/34.5% and 71.1%/28.9%) 
and the proportion of patients on different statin doses (20-80 
mg, p=0.26 for asymptomatic vs. symptomatic, and p=0.45 
for recently vs. remotely symptomatic). Concomitant fibrate 
use also did not differ between asymptomatic (4.5%) and 
symptomatic (3.7%) patients. All subjects were receiving an-
tiplatelet treatment with aspirin and/or thienopyridine. The 
absence of intergroup differences in clinical characteristics 
and medical therapy enabled biomarker profile comparisons 
with respect to CS symptoms.
The degree of angiographic ICA diameter stenosis did not 
differ between asymptomatic and symptomatic CS (medians 
of 67.4% vs. 65.7%, p=0.18). Within the group of symptom-
atic lesions, median angiographic CS severity by diameter 
stenosis was 66.5% in those with symptoms last symptom 
occurrence ≤6 months and 63.9% in those with last symp-
tom occurrence >6 months (p=0.08). As measured by IVUS, 
there was no overall difference in the atheroma burden be-
tween the asymptomatic and symptomatic subjects, with me-
dian (range) values of 83.0% (77.1-87.6%) vs. 82.7% (76.2-
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88.8%; p=0.87). However, the atheroma burden was signifi-
cantly (p=0.03) higher in those with recent symptoms of CS 
(84.6%; 76.9-89.8%) than in those with remote symptoms of 
CS (80.1%; 73.1-86.0%), consistent with inward plaque remo-
deling following its symptomatic rupture.18
Circulating biomarkers in asymptomatic and 
symptomatic patients with carotid stenosis
Circulating cytokines and blood lipid levels in the study gr-
oups are given in Table 2. While the levels of total cholesterol, 
low-density lipoprotein (LDL) cholesterol, and Lp(a) did not 
differ, those of high-density lipoprotein (HDL) cholesterol 
were significantly higher in the CS-asymptomatic subjects 
[1.30 mmol/L (range=1.1-1.5 mmol/L) vs. 1.08 mmol/L (ran-
ge=0.9-1.3 mmol/L), p<0.001]. The level of triglycerides 
(TGs) was significantly higher in the CS-symptomatic pa-
tients [1.31 mmol/L (range=0.9-1.7 mmol/L) vs. 1.42 mmol/L 
(range=1.1-1.9 mmol/L), p=0.03]. The distribution of HDL-
cholesterol levels (Fig. 1A) indicates a clear shift toward 
lower HDL-cholesterol values in those with symptomatic CS. 
In addition, the LDL-/HDL-cholesterol ratio was significantly 
higher in the CS-symptomatic patients [2.35 (range=1.7-2.9) 
vs. 2.05 (range=1.6-2.6), p=0.008]. However, there were no 
differences in the lipid profile between those with last symp-
tom occurrence ≤6 months and those with the last episode 
>6 months (Table 2), consistent with the concept that lipids 
are associated with a long-term (chronic) rather than acute 
risk of CS-symptomatic transformation.
The IL-6 level was significantly higher in the symptomatic 
patients [3.69 pg/mL (range=1.44-6.81 pg/mL) vs. 2.44 pg/mL 
(range=1.07-5.41 pg/mL, p=0.04)], but no between-group 
difference was found for the other studied interleukins (IL-
1β, IL-8, and IL-18) (Table 2). Although the median level of 
hsCRP was higher in the symptomatic subjects [2.11 mg/L 
(range=1.4-6.1 mg/L) vs. 2.08 mg/L (range=1.2-3.4 mg/L)], 
the overall difference did not reach statistical significance (p= 
0.07). Exclusion of subjects with an hsCRP exceeding 10 mg/L19 
(n=2, 1.8%, in the asymptomatic group; n=8, 6.7% in the 
symptomatic ≤6 months group; n=6, 8.4%, in the symptom-
atic >6 months group; in all cases, hsCRP values were ≤15 
mg/L) had no effect on the hsCRP analysis outcome (Table 2). 
Nevertheless, analysis of hsCRP distribution (Fig. 1B) indi-
cated that while both asymptomatic and symptomatic sub-
jects exhibited a prevalence peak at ≈2 mg/L, the symptom-
atic subjects exhibited a bimodal distribution with a nadir at 
≈5.2 mg/L and a second, smaller prevalence peak at ≈7 mg/
L. When this nadir was taken as a cutoff, there were 11.2% 
asymptomatic subjects vs. 27.7% symptomatic subjects with 
hsCRP ≥5.2 mg/L [odds ratio (OR)=3.06, 95% confidence in-
terval (95%CI)=1.51-6.22, p=0.002], indicating that hsCRP 
levels exceeding 5.2 mg/L may be associated with a signifi-
cant increase in the likelihood of CS-symptomatic status. 
However, hsCRP ≥5.2 mg/L could not differentiate between 
those with recent vs. remote symptoms of CS (p=0.727), con-
sistent with the potential chronic rather than acute association 
between hsCRP and the risk of CS-symptomatic transforma-
















Age, years 67 (60-71) 66 (60-72) 0.96 67 (61-73) 64 (59-69) 0.09
Gender: men, % (n) 59.1 (65) 67.4 (128) 0.15 68.1 (81) 66.2 (47) 0.79
Arterial hypertension, % (n) 86.4 (95) 90.5 (172) 0.20 89.9 (107) 91.5 (65) 0.84
Diabetes, % (n) 27.3 (30) 35.3 (67) 0.15 37.8 (45) 30.9 (22) 0.34
On insulin, % (n) 8.2 (9) 11.6 (22) 0.35 10.9 (13) 12.7 (9) 0.72
h/o MI 29.1 (32) 23.2 (44) 0.24 17.6 (21) 32.4 (23) 0.02
Smoking (current or past), % (n) 56.4 (62) 55.3 (105) 0.89 53.8 (64) 57.8 (41) 0.64
CAD, % (n) 67.3 (74) 66.3 (126) 0.87 61.3 (73) 74.7 (53) 0.09
PAD, % (n) 17.3 (19) 11.6 (22) 0.17 10.9 (13) 12.7 (9) 0.70
BMI 27.8 (25.9-30.2) 27.7 (25.5-30.1) 0.95 27.7 (25.5-30.1) 27.7 (25.5-30.1) 0.95
BMI ≥30 kg/m2, % (n) 28.2 (31) 27.9 (53) 0.98 28.6 (34) 26.7 (19) 0.89
Creatinine (µmol/L) 87.0 (74-103) 85.0 (74-99) 0.66 83 (74-97) 87 (76-104) 0.21
eGFR <60 mL/min (MDRD), % (n) 24.5 (27) 20.5 (39) 0.47 19.5 (23) 22.5 (16) 0.36
Index ICA peak systolic velocity, m/s 2.64 (2.02-3.5) 2.55 (1.9-3.3) 0.22 2.62 (1.9-3.5) 2.44 (1.9-3.2) 0.61
Index ICA end-diastolic velocity, m/s 0.87 (0.7-1.2) 0.86 (0.7-1.2) 0.86 0.87 (0.7-1.3) 0.84 (0.6-1.2) 0.56
Continuous data are median (Q1-Q3); categorical data are % (n).
BMI: Body Mass Index, CAD: coronary artery disease, eGFR: estimated Glomerular filtration rate, h/o MI: history of myocardial infarct, 
MDRD: modification of died in renal disease formula, PAD: peripheral arterial occlusive disease.
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tion. In addition, there was a weak but statistically significant 
negative correlation between HDL and hsCRP (r=-0.32, p< 
0.0001).
The plasma levels of the MMPs (MMP-8, MMP-9, and 
MMP-10) did not differ between the study groups (Table 2). 
In contrast, circulating TIMP was significantly lower in the CS-
symptomatic patients [130.0 ng/mL (range=7.3-166.5 ng/mL) 
vs. 146.2 ng/mL (range=115.3-177.9 ng/mL), p=0.02], indi-
cating a shift toward reduced metalloproteinase inhibition in 
subjects with symptomatic CS. The overall levels of fibrino-
gen, visfatin, CD40L, sVCAM, leptin, adiponectin (including 
leptin/adiponectin ratio), LP-PLA2, MCP-1, MPO, and OPG 
also did not differ between the symptomatic and asymptom-
atic patients. However, when the symptomatic patients were 
divided into those with recent vs. remote symptoms, the levels 
of LP-PLA2 and OPG were significantly higher in the recently 
CS-symptomatic subjects [0.33 µg/mL (range=0.3-0.4 µg/mL) 
vs. 0.31 µg/mL (range=0.2-0.4 µg/mL), p=0.02; 4.70 pg/mL 
(range=3.6-6.3 pg/mL) vs. 4.14 pg/mL (range=2.8-5.5 pmol/L), 
p=0.02].
Since patients for whom >6 months has elapsed since their 
last episode of CS-attributable neurological symptoms (i.e., 
those “remotely” symptomatic by the current study definition) 
are often classified as “asymptomatic”,1,16,20 the effect of merg-
ing this subset (n=71) with the a priori asymptomatic group 
(n=190) on the biomarker data was tested. Incorporation in 
















Total cholesterol (mmol/L) 4.5 (3.8-5.3) 4.4 (3.9-5.0) 0.31 4.38 (3.9-4.9) 4.43 (3.9-5.2) 0.42
LDL-cholesterol (mmol/L) 2.58 (2.0-3.2) 2.51 (2.1-3.0) 0.37 2.46 (2.0-2.9) 2.54 (2.1-3.1) 0.46
HDL-cholesterol (mmol/L) 1.30 (1.1-1.5) 1.08 (0.9-1.3) <0.001 1.07 (0.9-1.3) 1.11 (0.9-1.3) 0.74
LDL/HDL ratio 2.05 (1.6-2.6) 2.35 (1.7-2.9) 0.008 2.24 (1.7-2.8) 2.37 (1.9-3.0) 0.41
Triglycerides (mmol/L) 1.31 (0.9-1.7) 1.42 (1.1-1.9) 0.03 1.41 (0.9-1.8) 1.42 (1.2-2.0) 0.12
Lp(a) (mg/dL) 9.27 (4.1-17.3) 9.79 (4.1-23.6) 0.25 10.11 (4.1-27.1) 9.48 (4.0-19.4) 0.75
hs-CRP (mg/L) 2.08 (1.2-3.4) 2.11 (1.4-6.1) 0.07 2.37 (1.4-5.5) 1.93 (1.2-6.4) 0.47
hs-CRP (≤10)† (mg/L) 1.99 (1.2-3.3) 2.0 (1.2-3.9) 0.28 2.17 (1.3-3.9) 1.77 (1.1-2.8) 0.27
Fibrinogen (g/L) 4.44 (3.6-5.0) 4.11 (3.3-4.9) 0.19 3.96 (3.4-5.2) 4.13 (3.3-4.8) 0.62
IL-1β (pg/mL) 0.14 (0.1-0.2) 0.13 (0.1-0.2) 0.87 0.13 (0.1-0.2) 0.12 (0.1-0.2) 0.68
IL-6 (pg/mL) 2.44 (1.1-5.4) 3.69 (1.4-6.8) 0.04 3.41 (1.5-6.7) 4.16 (1.3-7.3) 0.94
IL-8 (pg/mL) 8.21 (5.3-11.4) 8.73 (5.8-11.9) 0.49 8.73 (6.3-12.0) 8.73 (4.9-13.3) 0.67
IL-18 (µg/mL) 0.33 (0.3-0.4) 0.32 (0.2-0.4) 0.78 0.33 (0.2-0.4) 0.32 (0.3-0.4) 0.47
sVCAM (mg/mL) 0.87 (0.7-1.1) 0.91 (0.7-1.2) 0.28 0.86 (0.7-1.1) 0.94 (0.7-1.2) 0.43
CD40L (ng/mL) 0.31 (0.2-0.5) 0.35 (0.2-0.5) 0.63 0.37 (0.2-0.5) 0.31 (0.2-0.4) 0.67
Lp-PLA2 (ng/mL) 326.9 (260-381) 319.7 (266-373) 0.65 328.8 (274-407) 310.4 (247-338) 0.02
Visfatin (ng/mL) 0.32 (0.2-0.6) 0.25 (0.1-0.5) 0.25 0.26 (0.2-0.6) 0.22 (0.1-0.5) 0.39
MCP-1 (ng/mL) 0.22 (0.2-0.3) 0.25 (0.2-0.3) 0.25 0.26 (0.2-0.3) 0.24 (0.2-0.3) 0.34
MPO (ng/mL) 45.4 (28.9-79.4) 48.3 (29.6-77.8) 0.82 49.1 (29.6-78.6) 47.5 (29.0-76.9) 0.88
MMP-8 (ng/mL) 20.0 (10.6-32.3) 20.2 (11.3-37.5) 0.42 19.7 (9.9-35.0) 24.5 (12.4-39.1) 0.40
MMP-9 (µg/mL) 0.13 (0.1-0.2) 0.14 (0.1-0.2) 0.36 0.13 (0.1-0.2) 0.16 (0.1-0.2) 0.29
MMP-10 (µg/mL) 0.66 (0.4-0.8) 0.58 (0.5-0.8) 0.63 0.56 (0.5-0.8) 0.66 (0.5-0.8) 0.12
TIMP (ng/mL) 146.2 (115-178) 130.7 (108-176) 0.02 130.6 (101-166) 131 (112-165) 0.75
Leptin (ng/mL) 12.15 (4.9-27.2) 11.37 (5.1-19.5) 0.57 11.06 (5.1-19.8) 12.18 (5.8-19.2) 0.70
Adiopnectin (μg/mL) 4.13 (2.9-5.9) 3.96 (2.7-6.6) 0.64 3.56 (2.3-6.7) 4.42 (3.0-6.5) 0.24
Leptin/adiponectin ratio 3.01 (1.0-6.3) 1.91 (0.9-5.6) 0.36 1.81 (0.9-5.4) 2.19 (0.9-7.3) 0.61
OPG (pmol/L) 4.28 (2.9-5.0) 4.45 (3.3-5.9) 0.21 4.71 (3.6-6.3) 4.13 (2.8-5.4) 0.01
Data are shown as median (Q1-Q3). 
*The terms “symptomatic” or “asymptomatic” refer to neurological symptoms attributable to carotid artery stenosis by an indepen-
dent neurologist, †Subjects with hsCRP ≥10 mg/L excluded (n=2 with asymptomatic carotid stenosis, n=8 symptomatic ≤6 months and 
n=6 with last symptoms >6 months; NB. the peak hsCRP level was 13.86 mg/L).
CD40L: soluble CD 40 receptor ligand, HDL: high-density lipoprotein, hs-CRP: high sensitivity C-reactive protein, IL: interleukin, LDL: low-
density lipoprotein, Lp(a): lipoprotein a, Lp-PLA2: lipoprotein-associated phospholipase A2, MCP: monocyte chemoattractant protein, 
MMP: matrix metalloproteinase, MPO: myeloperoxidase, OPG: osteoprotegerin, sVCAM: soluble vascular cell adhesion molecule, 
TIMP: tissue inhibitor of matrix metalloproteinases-1.
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the asymptomatic cohort of the patients with the last neuro-
logical symptoms occurring >6 months prior to biomarker 
sampling blunted the asymptomatic vs. symptomatic differ-
ence in HDL-cholesterol and removed the differences in LDL/ 
HDL-cholesterol, TGs, TIMP, and IL-6, indicating that sub-
jects with prior symptoms of CS remain distinct from the as-
ymptomatic group.
ROC analysis for CS-symptomatic status 
prediction
Receiver operating characteristics analysis included HDL, 
TIMP, and IL-6 (but not TGs, which showed a weak though 
significant negative correlation with the HDL level; r=-0.28, 
p<0.001). The highest area under the curve (AUC) was found 
for HDL-cholesterol (AUC=0.70, 95%CI=0.63-0.76, cut-
off=1.16 mmol/L, positive predictive value=0.78, negative pre-
dictive value=0.52) (Fig. 2A). IL-6 paired with TIMP performed 
similarly to HDL-cholesterol taken alone (Fig. 2B), but com-
bining all three biomarkers (i.e., HDL+IL-6+TIMP) did not 
surpass the diagnostic accuracy of HDL-cholesterol (Fig. 2C).
Lipoprotein-associated phospholipase A2 and OPG were 
significantly higher in those with CS symptoms occurring ≤6 
months vs. >6 months (Table 2) and were not interrelated (r= 
-0.09, p=0.32), and so their individual vs. combined power in 
the prediction of CS-recently vs. CS-remotely symptomatic sta-
tus was tested. A greater power was found for Lp-PLA2+OPG 
(AUC=0.70, 95%CI=0.60-0.78, p<0.01) when compared to 
the ROC for Lp-PLA2 alone (AUC=0.63, 95%CI=0.53-0.72, 
p=0.019, cutoff=361 ng/mL) or OPG alone (AUC=0.62, 95% 
CI=0.52-0.72, p=0.02, cutoff=3.73 pmol/L), consistent with 
the idea that Lp-PLA2 and OPG may affect plaque biology 
via different mechanisms.
Univariate and multivariate logistic regression 
models
Univariate and multivariate logistic regression analyses were 
performed to assess the role of angiographic stenosis severity 
and atheroma burden on intravascular ultrasound, and of HDL-
cholesterol, TIMP, IL-6, and TG level in predicting CS-symp-
tomatic status. In the univariate model, HDL-cholesterol and 
TIMP (but not IL-6 or TG) predicted the CS-symptomatic 
status (OR=2.51, 95%CI=1.73-3.65, p<0.001 for HDL-cho-
lesterol <1 mmol/L vs. >1.37 mmol/L; and OR=1.59, 95%CI= 
1.06-2.41, p=0.027 for TIMP <111 ng/mL vs. >204 ng/mL) 
(Table 3). The angiographic stenosis severity and atheroma 
burden as assessed by IVUS were not predictive of CS symp-
toms (p=0.16 and p=0.68, respectively). In a multivariate mo-
del, a low HDL-cholesterol level was the sole predictor of CS-
symptomatic status (OR=1.81, 95%CI=1.15-2.84 for HDL-
cholesterol <1 mmol/L vs. >1.37 mmol/L, p=0.01) (Table 3).
Discussion
The key finding of this study, which evaluated the largest up-
to-date panel of circulating biomarkers in subjects with CS, is 
that low HDL-cholesterol was the sole independent predictor 
of CS-symptomatic status in a contemporary CS population. 
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Fig. 1. Distributions of HDL-cholesterol 
and hsCRP* in patients with carotid st-
enosis according to the presence or ab-
sence of a history of carotid stenosis-
associated symptoms. A: Displays HDL-
cholesterol level distribution (asympto-
matic carotid stenosis top, A1; sympto-
matic carotid stenosis bottom, A2). B: 
hsCRP level distribution (asymptomatic 
carotid stenosis top, B1; symptomatic 
carotid stenosis bottom, B2). HDL: high-
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symptoms increased by a factor of 1.81 (95%CI=1.15-2.84) 
between the first and fourth HDL-cholesterol quartiles. De-
spite statistically significant differences in IL-6, TIMP, and TG 
level between the CS-symptomatic and CS-asymptomatic 
subjects, in the multivariable model these biomarkers were not 
independent predictors of CS symptoms. Moreover, their ad-
dition to HDL-cholesterol failed to provide any incremental 
value over HDL-cholesterol alone in the ROC analysis (Fig. 2). 
Thus, the findings of the present study in an unselected pop-
ulation of CS subjects on contemporary pharmacotherapy 
are unable to confirm the clinical utility of several circulating 
biomarkers that have previously been suggested to indicate the 
symptomatic status of CS, including hsCRP,4,5 IL-6,4,21 Lp(a),4 
and MMPs.4,6 Moreover, this analysis did not demonstrate 
the utility of several other classic (e.g., CD40L, sVCAM, fi-
brinogen, IL-1β, IL-8, IL-18, MPO, and MCP-1)4,11 and novel 
(e.g., visfatin and leptin/adiponectin)7,9,22 circulating biomark-
ers of atherosclerotic plaque destabilization and rupture.
Subjects with symptomatic CS demonstrated a reduced le-
vel of circulating TIMP, consistent with dysregulation of the 
MMP/TIMP balance in patients with symptomatic CS, result-
ing in decreased endogenous inhibition of MMPs.23 Although 
Fig. 2. ROC curves for determining the symptomatic status of CS. 
Biomarker(s) sensitivity is demonstrated as a function of 1-specificity 
based on a logistic model incorporating three uncorrelated biomark-
ers (HDL-cholesterol, TIMP, and IL-6) whose levels differed signifi-
cantly between symptomatic and asymptomatic subjects. A: Contri-
bution of each biomarker taken alone; the AUC was highest for HDL-
cholesterol. B: Contributions of paired biomarkers, indicating that 
neither of the pairs has a higher diagnostic power than HDL-choles-
terol alone (cf. A). C: ROC curve for combined HDL-cholesterol+IL-
6+TIMP, indicating that this was not higher than for HDL-cholesterol 
alone (cf. A). AUC: area under the curve, CS: carotid stenosis, HDL: 
high-density lipoprotein, IL-6: interleukin-6, ROC: receiver operating 
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AUC 95%CI Cutoff Sensitivity Specificity PPV NPV
HDL 0.70 0.63-0.76 1.16mmol/L 0.62 0.71 0.78 0.52
TIMP 0.60 0.52-0.68 122ng/mL 0.45 0.72 0.72 0.45
Il-6 0.59 0.50-0.67 3.66 pg/mL 0.51 0.67 0.72 0.45
AUC 95%CI Sensitivity Specificity PPV NPV
HDL+TIMP 0.67 0.59-0.74 0.69 0.58 0.72 0.54
HDL+IL-6 0.66 0.58+0.73 0.58 0.65 0.73 0.49
Il-6+TIMP 0.70 0.64-0.76 0.62 0.73 0.79 0.53
AUC 95%CI Sensitivity Specificity PPV NPV
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the overall levels of Lp-PLA2 and OPG did not differ between 
those with and without CS symptoms, these two biomarkers 
were significantly elevated in subjects with recent vs. remote 
CS symptoms. Both Lp-PLA2 and OPG promote plaque in-
stability and rupture.4,8 The present finding is in line with re-
cent histological evidence of significantly increased Lp-PLA2 
and OPG expression in carotid plaques in patients neurologi-
cally symptomatic during the preceding 1.5-4 months,4,8 and 
OPG prediction of premature atherosclerosis progression in 
asymptomatic normotensive individuals.24 Furthermore, the 
absence of a correlation between levels of Lp-PLA2 and OPG 
(r=-0.09, p=0.32) is consistent with their independent action 
in promoting plaque instability. Incorporation of both Lp-
PLA2 and OPG in the ROC analysis increased their individu-
al AUC in the determination of recently symptomatic CS sta-
tus (AUC=0.63 for Lp-PLA2, 0.62 for OPG, and 0.70 for Lp-
PLA2+OPG).
“Symptomatic” status of the carotid stenosis
There is currently no single, generally applied definition of 
symptomatic CS with respect to the time elapsed since the last 
symptom episode. For example, the term “asymptomatic” 
has been used not only to label patients with no history of ipsi-
lateral symptoms,10,25 but also to those with prior symptoms 
who have been free of neurological events for a period from 
1-4 months8 to 12 months,6 with the cutoff for the CS symp-
tom-free period frequently taken as 6 months.1,16,20 With these 
varying definitions, subjects with a history of CS symptoms 
during the previous 1-12 months have been classified in dif-
ferent previous studies either as “symptomatic” or “asymp-
tomatic.”8,20,26,27 Data from these studies,8,20,26,27 when consid-
ered on aggregate, suggest that the use of different definitions 
of CS “symptomatic” status could have a significant impact 
on the findings. For clarity of analysis, in the present study all 
patients with history of CS symptoms were considered “symp-
tomatic”. Moreover, the applied cutoff of 6 months for distin-
guishing those with recent vs. remote symptoms is consistent 
with recent histological evidence that most carotid plaques 
stabilize within 6 months after the neurological event.25
There is experimental evidence4,10,25 that certain biomarkers 
have a chronic effect on carotid plaque stability (e.g., low HDL, 
low TIMP, and elevated IL-6), whereas others (possibly LP-
PLA2 and OPG) have a more transient impact or acutely re-
flect plaque destabilization. Several previous studies23,28 have 
interpreted the serum biomarker level in the context of plaque 
histology rather than of the neurological symptoms of carotid 
plaque rupture and thrombosis. Indeed, it is well known that 
carotid plaques can undergo several episodes of rupture and 
thrombosis that may remain clinically silent, although they 
usually lead to plaque progression.29,30 Our finding that inclu-
sion of the remotely symptomatic subjects in the asymptom-
atic group reduced or abolished the between-group differences 
in circulating biomarkers is consistent with the concept that 
the circulating biomarker profile of subjects with remote symp-
toms of CS may remain at least partially different from that 
of never-symptomatic subjects.
Systemic biomarker concentration vs. in-situ 
plaque destabilization and rupture
In an ideal setting of the assessment of circulating biomarkers 
in relation to CS clinical symptoms, either the release of the 
biomarker from the index lesion should be sufficiently high 
to affect its systemic level or a “causative” circulating bio-
marker released elsewhere should exclusively affect stability 
of the index-in this case carotid-lesion under consideration. 
This is not necessarily the case because instability of the ath-
erosclerotic lesion(s) in one vascular bed (e.g., carotid) is of-
ten associated with instability of atherosclerotic lesion(s) in 
other beds (e.g., coronary)30 through “vulnerable blood” 
mechanisms.31,32 The available data suggest that atheroscle-
rotic plaque destabilization and rupture in one specific vascu-
lar territory involves an interplay between the local (in situ) 
factors7,33-35 that make a particular plaque prone to erosion or 
rupture (“vulnerable plaque”) and systemic factors (“vulner-
able blood”).31,32 Thus, the circulating biomarker level actually 
reflects the net effect of 1) biomarker production and release 
in the “target” atherosclerotic lesion, with a local release pos-
sibly too small to be detected systemically6,27,34 and/or occur-
ring only transiently;25 2) the contribution of biomarker release 
from atherosclerotic plaques in other vascular territories; and 
3) for some biomarkers, their production elsewhere (e.g., the 
liver in the case of fibrinogen or hsCRP).22,26,36
Table 3.  Univariate and multivariate logistic regression analysis for the prediction of carotid artery stenosis symptomatic status
Marker Model <1st quartile vs. 3rd quartile OR 95% Cl p value
HDL-cholesterol (mmol/L) Univariate <1.00 vs. >1.37 2.51 1.73-3.65 <0.001
TIMP (ng/mL) Univariate <111 vs. >204 1.59 1.06-2.41 0.027
IL-6 (pg/mL) Univariate <1.28 vs. >6.15 0.73 0.49-1.09 0.106
Triglycerides (mmol/L) Univariate <1.05 vs. >1.85 0.73 0.52-1.03 0.072
HDL-cholesterol (mmol/L) Multivariate <1.00 vs. >1.37 1.81 1.15-2.84 0.010
TIMP (ng/mL) Multivariate <111 vs. >204 1.49 0.96-2.31 0.073
HDL: high-density lipoprotein, IL: Interleukin, OR: odds ratio, TIMP: tissue inhibitor of matrix metalloproteinases-1.
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Several previous studies of the relationship between circu-
lating biomarkers and carotid atherosclerosis have either ex-
cluded patients with atherosclerosis in other vascular territo-
ries35 or have used combined end points (e.g., death/TIA/st-
roke/myocardial infarction, or any revascularization and/or 
carotid plaque progression) to identify a biomarker utility in 
relation to CS-symptomatic status.9,13,15,26,32 In addition, con-
temporary pharmacotherapy, which involves a high propor-
tion of statin and angiotensin-converting enzyme inhibitor use, 
may play an important role in reducing the level of inflamma-
tory markers and/or weaken the relationship between biomark-
ers and the risk of symptomatic plaque transformation.37-39
Low HDL-cholesterol as an independent 
predictor of CS-symptomatic status
High-density lipoprotein-cholesterol protects against athero-
sclerosis via several anti-inflammatory, antioxidant, and anti-
thrombotic effects, including reverse cholesterol transport in 
the liver, prostacyclin release, and the inhibition of endotheli-
al adhesion molecule expression, monocyte chemotactic ac-
tivity, and LDL oxidation.40 Our novel finding of HDL-chole-
sterol as an independent predictor of CS-symptomatic status 
in patients with established carotid atherosclerosis is consis-
tent with the association between low HDL-cholesterol with 
the unstable carotid plaque phenotype on conventional his-
tology.30 It is also consistent with the finding of low HDL-ch-
olesterol more frequent in stroke and TIA patients with ath-
erosclerotic large-vessel stenosis than in those with stroke/TIA 
in the absence of atherosclerotic large-vessel stenosis.41 The 
failure of previous studies to identify a link between low HDL-
cholesterol and the neurological symptoms of carotid athero-
sclerosis may have been due to the inclusion of relatively 
small samples and/or the classification of the patients with last 
symptoms of CS >3-6 months as asymptomatic,8 which would 
blunt any potential differences between the truly asymptom-
atic vs. those with prior symptoms of CS. Previous work sug-
gested a protective role for high HDL-cholesterol levels ag-
ainst the progression of carotid atherosclerosis rather than its 
symptomatic conversion;4 there is also recent prospective evi-
dence that increased HDL-cholesterol protects against the pro-
gression of intracranial atherosclerosis.43
The CS severity was similar in the symptomatic and as-
ymptomatic subjects included in the present study, which sup-
ports the concept of a protective role played by high HDL-cho-
lesterol through reducing the risk of symptomatic transform-
ation of the carotid plaque. A recent study of left main co-
ronary artery atherosclerosis44 indicated that a low HDL/LDL-
cholesterol ratio may be related to an increased lipid content 
and smaller fibrous content observed on the plaque radiofre-
quency IVUS imaging, possibly rendering the atherosclerotic 
plaque more amenable to symptomatic transformation. Such 
an association is yet to be evaluated for carotid bifurcation 
atherosclerotic disease.
Limitations
While this study employed the most extensive up-to-date pa-
nel of biomarkers in patients with carotid atherosclerosis, the 
discriminative power of remnant lipoprotein cholesterol,43,45 
which was shown recently to be a risk factor for large-artery 
atherosclerotic stroke,46 was not evaluated. Secondly, due to 
the natural history of carotid atherosclerosis, the CS cohort 
labeled “asymptomatic” is known to include up to ≈10-15% 
of subjects whose CS is likely to turn symptomatic over the 
subsequent 10 years.3 This natural presence of future-symp-
tomatic subjects in the thus-far-asymptomatic group (both 
labeled “asymptomatic”) may obscure biomarker profile dif-
ferences in a cross-sectional study. Moreover, in search of 
patient characteristics that might aid clinical decision-making 
in an all-comer population with CS, we deliberately avoided 
any preselection of study subjects.47 Thus, the present study 
cohort included a sizeable proportion of patients with estab-
lished (and/or symptomatic) atherosclerosis in other vascular 
territories (Table 1). This is likely to blunt any differences in 
the circulating biomarker profiles between the study groups. 
Finally, the finding that circulating OPG and Lp-PLA2 might 
transiently label symptomatic transformation of the carotid 
atherosclerotic plaque warrants further, prospective48 valida-
tion in a large “natural history” study with 1) repeated (serial) 
biomarker sampling to enable a change in biomarker level 
“just” prior to symptom occurrence, and 2) ideally, repeated 
carotid plaque imaging. However, due to the relatively low 
event rate in subjects with asymptomatic carotid stenosis on 
contemporary pharmacotherapy and the unavoidable cross-
over of some patients to mechanical revascularization, such 
a large longitudinal study is unlikely to be conducted.
Conclusions
The present analysis in patients with CS subjected to con-
temporary pharmacotherapy found that among several circu-
lating biomarkers that have previously been implicated in in-
dicating carotid plaque destabilization and symptomatic tr-
ansformation, low HDL-cholesterol was the only independent 
predictor of neurological symptoms. This finding is consistent 
with the detrimental effect of low HDL-cholesterol in patients 
with clinical manifestation of atherosclerosis in some other 
vascular beds,39 indicating that the HDL-cholesterol level sh-
ould be considered in the routine risk stratification of asymp-
tomatic carotid stenosis. The findings also suggest that low 
HDL-cholesterol could constitute an important therapeutic 
target in subjects with carotid stenosis. Nevertheless, the ex-
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tents to which a low HDL-cholesterol level is a causal factor 
versus an epiphenomenon have not been determined.40 More-
over, there is recent evidence that forced elevation of defective 
HDL-cholesterol is clinically ineffective.40 Therefore, whether 
(and which) pharmacologic interventions aimed at increasing 
HDL-cholesterol would actually reduce the risk of carotid pla-
que symptomatic transformation has to be demonstrated.
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